Roche Diagnostics up 5 Percent in H1 2012, MDx up 6 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Roche today reported that sales in its diagnostics division grew 5 percent year over year at constant exchange rates during the first half of 2012 while the molecular diagnostics business grew 6 percent.

For the six months ending June 30, the Swiss drug and diagnostics firm reported diagnostic sales of CHF 5.01 billion ($5.13 billion) compared to CHF 4.86 billion during the first half of 2011. In Swiss francs the division grew 3 percent, and in dollars first-half 2012 sales were up 1 percent year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.